推薦產品
等級
pharmaceutical primary standard
API 家族
norfloxacin
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3
InChI
1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
InChI 密鑰
OGJPXUAPXNRGGI-UHFFFAOYSA-N
尋找類似的產品？ 前往 產品比較指南
相關類別
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Norfloxacin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化／生理作用
诺氟沙星通过干扰 ATP 诱导转换 DNA 与 DNA 旋转酶（拓扑异构酶）复合物的结构转换而阻断 DNA 复制。
操作方式：抑制细菌 DNA 复制
抗菌谱：革兰氏阴性菌； 对革兰氏阳性菌效果较差
操作方式：抑制细菌 DNA 复制
抗菌谱：革兰氏阴性菌； 对革兰氏阳性菌效果较差
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
產品號碼
描述
訂價
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
D E Nix et al.
Clinical pharmacy, 6(2), 105-117 (1987-02-01)
The chemistry, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of ciprofloxacin and norfloxacin are reviewed, and mechanisms of antimicrobial resistance and drug and laboratory interactions are described. Norfloxacin is the first antimicrobial in
J S Wolfson et al.
Annals of internal medicine, 108(2), 238-251 (1988-02-01)
Norfloxacin is an oral fluoroquinolone antimicrobial agent recently released for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication. Norfloxacin is more potent and broader in spectrum than
Jessica M A Blair et al.
The Journal of antimicrobial chemotherapy, 70(2), 424-431 (2014-10-08)
Enterobacteriaceae have multiple efflux pumps that confer intrinsic resistance to antibiotics. AcrB mediates clinically relevant multidrug resistance and is required for virulence and biofilm formation, making it an attractive target for the design of inhibitors. The aim of this study
Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.
D R Nalin
European journal of cancer & clinical oncology, 24 Suppl 1, S55-S61 (1988-01-01)
Ying-Jun Zhou et al.
FEMS microbiology letters, 355(2), 124-130 (2014-05-13)
The antimicrobial activity of one 3-hydroxypyridin-4-one (HPO) hexadentate (1) and three HPO hexadentate-based dendrimeric chelators (2-4) was evaluated. They were found to exhibit marked inhibitory effect on the growth of two Gram-positive bacteria and two Gram-negative bacteria. The combination treatment
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務